Readystate Asset Management LP Raises Stock Position in Perrigo Company plc $PRGO

Readystate Asset Management LP lifted its stake in Perrigo Company plc (NYSE:PRGO) by 50.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 274,684 shares of the company’s stock after buying an additional 92,058 shares during the period. Readystate Asset Management LP owned approximately 0.20% of Perrigo worth $2,950,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Amundi boosted its stake in Perrigo by 11.7% in the first quarter. Amundi now owns 5,292 shares of the company’s stock valued at $148,000 after acquiring an additional 556 shares in the last quarter. Kestra Investment Management LLC lifted its holdings in shares of Perrigo by 57.1% in the 2nd quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock valued at $47,000 after purchasing an additional 642 shares during the last quarter. Geneos Wealth Management Inc. boosted its position in shares of Perrigo by 439.1% in the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after purchasing an additional 786 shares during the period. EverSource Wealth Advisors LLC boosted its position in shares of Perrigo by 116.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock valued at $26,000 after purchasing an additional 1,014 shares during the period. Finally, Covestor Ltd grew its stake in Perrigo by 14.4% during the 4th quarter. Covestor Ltd now owns 8,991 shares of the company’s stock worth $125,000 after buying an additional 1,129 shares during the last quarter. 95.91% of the stock is currently owned by institutional investors and hedge funds.

Perrigo Stock Performance

Shares of PRGO stock opened at $10.27 on Wednesday. The stock’s 50-day moving average price is $10.59 and its 200 day moving average price is $11.71. The company has a quick ratio of 1.59, a current ratio of 2.72 and a debt-to-equity ratio of 1.45. The stock has a market capitalization of $1.42 billion, a PE ratio of -0.78, a price-to-earnings-growth ratio of 1.20 and a beta of 0.51. Perrigo Company plc has a 52-week low of $9.23 and a 52-week high of $28.22.

Perrigo (NYSE:PRGO) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The company had revenue of $841.80 million during the quarter, compared to analysts’ expectations of $1.04 billion. During the same period last year, the firm earned $0.60 EPS. The firm’s revenue for the quarter was down 7.2% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, equities research analysts forecast that Perrigo Company plc will post 2.11 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Weiss Ratings upgraded Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 21st. Zacks Research raised shares of Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. One research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $19.33.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.